CHICAGO, IL—Treating patients with type 2 diabetes and a history of stable coronary artery disease with empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), a sodium-glucose co-transporter 2 ...
Patients with type 2 diabetes treated with the SGLT2 inhibitor empagliflozin during the landmark EMPA-REG OUTCOME trial had a solidly reduced need to either start insulin treatment or intensify ...
John B. Buse, MD, PhD: The EMPA-REG trial was a trial of empagliflozin versus placebo. It studied 2 different doses of empagliflozin, 10 mg and 25 mg once a day, versus matched placebo, and went on ...
ORLANDO, Florida — Results from the EMPA-Kidney trial of the SGLT2 inhibitor empagliflozin in people with chronic kidney disease (CKD) with or without diabetes did more than add a second positive ...
Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 inhibitor, reduced the risk of major ...
Dennis P. Scanlon, PhD: Welcome to The American Journal of Managed Care ® Peer Exchange TM, “Diabetes Therapy and Cardiovascular Outcomes: An Update.” My name is Dr Dennis Scanlon, and I’m a professor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results